Commercial Medical Devices

MedTech AI progress depends on data, process and governance foundations, summit hears

At the Veeva MedTech Summit in Amsterdam, Medtronic and keynote speakers argued that reliable data, harmonised processes and embedded governance must come before scaled AI adoption.

Ivo PetrovNovember 8, 20265 min read7 views
A translucent network of glowing nodes hovers above interlocking foundation layers in cool blue light.

MedTech organisations looking to deploy artificial intelligence are being urged to fix the fundamentals first — reliable data, consistent processes, appropriate governance and clear ownership — rather than chase rapid adoption. That was the central message from this year's Veeva MedTech Summit in Amsterdam, where speakers discussed what stands between promising pilots and scaled use.

Across presentations, panel discussions and interviews at the event, a consistent theme emerged: introducing AI into fragmented or inconsistent environments can create more problems than it solves. Without trustworthy information and standardised processes, organisations risk producing outputs that are difficult to trust, validate or scale.

Medtronic's four-year groundwork

Becki Brasher of Medtronic described the company's four-year journey towards being ready to implement AI. The work did not begin with the technology itself. Medtronic focused instead on harmonising processes, improving data consistency, consolidating systems and establishing appropriate governance structures.

Brasher summarised the approach during her conference session: the company did not start with AI, she said — it had to earn it.

Her account also stressed preparing employees for change. Technology alone cannot deliver transformation, and staff need the knowledge, confidence and oversight arrangements to incorporate new tools into their everyday responsibilities.

Governance embedded from the outset

Balancing technological innovation with regulatory compliance was another major theme, particularly during the closing keynote given by Erik Orzechowski and Benjamin Rochette. As AI adoption accelerates, they argued, MedTech organisations must find ways to move quickly without compromising the quality, safety and regulatory standards expected of the sector.

A key argument from their discussion was that governance should be embedded into technology development from the outset rather than treated as a final compliance exercise. That requires closer collaboration between IT, Quality and Regulatory teams: IT understands the technology and its implementation, while Quality and Regulatory professionals help assess risks and determine the evidence required to demonstrate compliance.

The speakers also called for proportionate governance. An AI application supporting relatively low-risk administrative activities does not necessarily require the same level of control as one influencing patient safety or regulatory decisions. Establishing clear responsibilities, risk assessments and appropriate controls early can create a more flexible approach that supports innovation without overlooking obligations, with compliance and innovation framed as complementary rather than opposing priorities.

Human judgement and the trust question

Despite the growing capabilities of AI, the summit underlined the continuing importance of human judgement and professional expertise. Brasher made clear her view that AI should assist human reviewers rather than replace them, and said in an interview that human judgement will stay in place as it is today until trust is built that what AI agents deliver is accurate.

AI can analyse large volumes of information, generate documentation and provide recommendations, but its outputs still require scrutiny: a convincing answer is not necessarily a correct one, particularly in a highly regulated environment. The closing keynote compared relying on AI without understanding its underlying subject matter to using a calculator without knowing the mathematics behind it — raising the question of how organisations can introduce AI into everyday workflows without undermining the expertise needed to challenge its outputs, especially for the next generation of regulatory and quality professionals.

Pilots, measurable value and pace

On value, the closing keynote identified time savings, reduced process cycle times, less rework, improved quality and employee adoption as ways to assess AI investments. With an increasing number of potential applications available, organisations were advised to resist pursuing every opportunity at once and instead target existing operational challenges with clear measures of success, starting with controlled pilot projects that retain human oversight before expanding what works.

Because both the technology and regulatory expectations will keep evolving, governance structures need to adapt alongside new capabilities. The message from the summit was that success will depend less on the number of AI initiatives launched than on the ability to turn promising applications into reliable, scalable business capabilities — and that sometimes, as Orzechowski put it, organisations need to slow down in order to speed up.